BIOGEN INC. is 9.9x more valuable than Beam Therapeutics Inc. by market capitalization ($29.53 B vs $2.99 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BEAM | BIIB |
|---|---|---|
| Market cap | $2.99 B | $29.53 B |
| US-listed rank | #1828 | #476 |
| Revenue (latest FY) | $139.74M | $9.89B |
| Net income (latest FY) | -$79.99M | $1.29B |
| Net margin | -57.2% | 13.1% |
| P/E (trailing FY) | - | 22.8 |
| SEC filings | 488 | 2,690 |
BIOGEN INC. is 9.9x more valuable than Beam Therapeutics Inc. by market capitalization ($29.53 B vs $2.99 B).
In their latest fiscal years, Beam Therapeutics Inc. reported $139.74M in revenue while BIOGEN INC. reported $9.89B.
Full pages: Beam Therapeutics Inc. and BIOGEN INC., or browse the full rankings.